VRDN Viridian Therapeutics, Inc.

bullish · high conviction track record →
Get emailed when VRDN changes direction
Mkt Cap $1B 52wk $11.76 - $34.29 3h ago
Insider buying: $40,616,302 bought by 5 insiders (30d)
Factor divergence: DIVERGENCE: insider_activity bullish vs estimate_revisions, analyst_revisions bearish
Est. revisions: -3.1%
Backed by structured data (insider trades, analyst ratings, or filings)
Factor Model (net -1.3)

Factor Model

net -1.3
Est. Revisions
-0.2
Insider Activity
+0.5
Momentum
+0.0
Analyst Rev.
-1.0
Narrative Gap
+0.0

Viridian insiders buy $40M, trial drives 13% gain

Watch: Watch upcoming regulatory updates on elegrobart as they will confirm market access and potential revenue ramp.

Viridian Therapeutics insiders led by FAIRMOUNT FUNDS MANAGEMENT LLC bought $40M stock at prices between $18.75 and $22. Insider buying includes $499K and $117K by officers. The REVEAL-1 phase 3 trial succeeded with strong results on primary endpoints for thyroid eye disease treatment, lifting VRDN stock 12.7% YoY despite YTD down 52%. Wall Street targets average $32.33.

Strong insider conviction paired with a successful pivotal trial underpins potential revaluation and recovery from a 51.8% YTD decline in a volatile biotech sector.

Evidence

Updated Friday Insider buy by FAIRMOUNT FUNDS MANAGEMENT LLC (VRDN): $30,000,000
Updated Friday Insider buy by MAHONEY STEPHEN F (VRDN): $499,262
Updated Friday Insider buy by BEETHAM THOMAS W (VRDN): $117,050
Updated Friday Insider buy by FAIRMOUNT FUNDS MANAGEMENT LLC (VRDN): $9,999,990
Updated Thursday Viridian Therapeutics (VRDN) Stock Posts Double-Digit Growth Year-on-Year yahoo-finance
59d ago Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake yahoo-finance
Fundamentals & Data ▾
Viridian Therapeutics, Inc. Healthcare · Biotechnology
Mkt Cap
$1B
Beta
1.17
52w Range
$11.76 - $34.29
Short Interest
10.8M 10.98%
Days to Cover
5.3 +39%
Insiders
buying 4B / 1S
EPS Estimate
$-1.08 -3.1% 30d 0up / 1dn
Est. Dispersion
33% 11 analysts
Analyst Target
$34 $20 - $50
Options P/C
0.83
Insider Cluster
strong buy 3B / 1S (officer)
Fund Convergence
moderate D.E. Shaw, Citadel
Top Holders
D.E. Shaw $61M
Citadel $22M
Recent Filings & Data
insider trade 10
net buying · $70,796 sold · $40,616,302 bought
5 insiders · 10 transactions (30d)
Recent transactions
BEETHAM THOMAS W · other
MAHONEY STEPHEN F · other
HARMON SETH · other
TOUSIGNANT JENNIFER · other
TOUSIGNANT JENNIFER · sell · $70,796
FAIRMOUNT FUNDS MANAGEMENT LLC · buy · $9,999,990
FAIRMOUNT FUNDS MANAGEMENT LLC · exercise · $166,355
BEETHAM THOMAS W · buy · $117,050
MAHONEY STEPHEN F · buy · $499,262
FAIRMOUNT FUNDS MANAGEMENT LLC · buy · $30,000,000
6 signals · latest Updated Friday

Get alerted when VRDN changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.

All stocks → Our calls → How it works →